{{Rsnum
|rsid=7517671
|Chromosome=1
|position=208945543
|Orientation=plus
|GMAF=0.3572
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 6.2 | 36.6 | 57.1
| HCB | 9.5 | 56.9 | 33.6
| JPT | 25.9 | 45.5 | 28.6
| YRI | 23.3 | 46.6 | 30.1
| ASW | 8.8 | 49.1 | 42.1
| CHB | 9.5 | 56.9 | 33.6
| CHD | 21.1 | 43.1 | 35.8
| GIH | 21.0 | 43.0 | 36.0
| LWK | 23.9 | 45.0 | 31.2
| MEX | 8.8 | 36.8 | 54.4
| MKK | 17.4 | 51.0 | 31.6
| TSI | 6.9 | 40.6 | 52.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7517671
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.28, combined P value= 5.05E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470243
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7517671
|overall_frequency_n=51
|overall_frequency_d=128
|overall_frequency=0.398438
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=44
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}